ClinicalTrials.gg
Enrolling by invitationNCT06034392CHAMPUpdated Nov 18, 2026

CHAMP App Cardiac Study and Repository

An observational study in Heart Defects, Congenital and Pediatrics, sponsored by Lori Erickson. Enrolling by invitation at 9 sites in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Lori Erickson · Observational

How we know

Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 356 studies in Heart Defects, Congenital with a site in United States — 67 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.

Planned enrollment
21st of 167
1,000 · median 72
Started
2023
with 17 others
Observational
170 of 356
36 open now
Primary completion
2027-12
later than 52 of 86 live
Registered
310th of 356
by date

Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 21st largest by planned enrollment of the 167 observational ones that give a count, is one of 18 that started in 2023, is one of 170 observational ones, reaches primary completion later than 52 of the 86 other live ones, and was the 310th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

67 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:

62 more — sign in →

All 67 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Heart Defects, Congenital with a site in United States, or all of them as a file.
02

Study summary

This is a multi-site research study with an optional research repository that will consist of clinically derived data and photographic or video images of patients in the home setting with complex health conditions to evaluate the safety and efficacy of the CHAMP® software platform, with data and photographic or video images input and/or uploaded by the parent or other legally authorized representative (LAR) of patients with complex congenital heart disease as a target population.

Read the detailed description

Study objectives

  1. To evaluate whether data collection and transmission through the CHAMP software platform improves communication between health care providers and parents/LAR that positively affects the care of children with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated
  2. To determine the accuracy of data obtained regarding observation by parent or caregiver of the condition of children with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated.
  3. To evaluate the use of the CHAMP App for clinical purposes, including user satisfaction with the data entry, parental self-management, and transmission capabilities.
  4. To evaluate the real-world performance analytics (RWPA) of the CHAMP software platform for transfer of parent-entered data for children with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated.

Endpoints

  1. To demonstrate that parents and caregivers for children with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated can accurately identify and transmit to healthcare providers specific health-related data including intake of food, fluids and mediations; output, including urination, defecation, and vomiting; weight; vital signs including oxygen saturation as measured by pulse oximetry; heart rate as measured either by a heart rate monitor or manually by the parent or caregiver; and temperature, measured by a reliable thermometer; and the value and reliability of videos provided by parents and caregivers regarding behavior of pediatric study participants for use in evaluating participant's health status.
  2. To demonstrate that data obtained through the use of devices such as pulse oximeters, as entered into the app by parents and caregivers, provide valuable information regarding the health status of children with Complex Diagnoses in a home setting.
  3. To demonstrate characteristics of CHAMP through real world health analytics (RWHA), user experience analytics (UX), and product performance analytics (PPA).

The study duration is open-ended for safety, effectiveness, and performance of the CHAMP app. Unless consent is withdrawn, data will be kept and used for data analysis and, if consented to the research repository for multi-site research purposes indefinitely. At age 18, previously pediatric patients may be approached for reconsent.

03

Conditions studied

  • Heart Defects, Congenital
  • Pediatrics

Keywords

  • mHealth
  • Software Platform
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients with complex congenital heart disease in which asynchronous monitoring in the home setting is indicated in the home setting through a multi-regional approach.

Parents who utilize their CHAMP App and the healthcare team that log-in are also part of the CHAMP App study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 0-17 years with a parent/Legally authorized representative
  • Diagnosed with a complex health condition in which asynchronous monitoring in the home setting is appropriate.
  • Pediatric patient's cardiac care team has decided that the patient's treatment plan may benefit from remote home monitoring.
  • Institution that the subject is followed through clinically has been an approved as site for the CHAMP app study with Children's Mercy Kansas City.

Adult participants

  • Parents/Legally authorized representatives of pediatric subject.
  • Healthcare team users at an institution that is an approved site for the CHAMP app Study with Children's Mercy Kansas City.

Exclusion criteria

Exclusion Criteria:

  • Inability to be discharged to care in the home setting.
  • Those not meeting the above inclusion criteria.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • DeviceCHAMP App

    CHAMP® App is a downloadable software mobile Application with a Software Platform. CHAMP® App is an electronic version of data entry for children with conditions that require close monitoring from their homes. The primary Intended Use is to relay monitoring information from homes to the health care team. This monitoring includes data options that can facilitate the collection of monitoring data of children in the home setting to improve communications between parents at home and remote caregivers. The CHAMP® App itself does not do home monitoring of the child's medical condition. It is not designed to alert parents if data entered has reached a red flag (problem) level. Users of the CHAMP App are advised in writing and in the informed consent process that urgent medical conditions should not be managed through the CHAMP App, and that appropriate emergency care should be obtained directly rather than through the CHAMP App.

06

What researchers measure

Primary outcomes

  1. Human factors/usability engineering: Login failures

    Rate of attempts of log-in failures

    Time frame: Over a 3 month period

  2. Human factors/usability engineering: Imprecision

    Rate of data values reported with imprecision

    Time frame: Over a 3 month period

  3. Clinical Safety: Anticipated adverse events

    Anticipated Adverse event rates

    Time frame: Over a 3 month period

  4. Clinical Safety: Event resolution- anticipated

    Time to resolve anticipated adverse events

    Time frame: Time in days, reported over the last 3 months

  5. Clinical Safety: Unanticipated Adverse events

    Unanticipated adverse event rates

    Time frame: Time in days, reported over the last 3 months

  6. Clinical Safety: Event resolution- unanticipated

    Time to resolve unanticipated adverse events

    Time frame: Time in days, reported over the last 3 months

  7. Health Benefits: Adherence

    Rate of adherence to daily data entry

    Time frame: Measurement of adherence to daily data entry per each patient/parent over 3 month period on non-hospitalized days, during the study period

  8. User Satisfaction: Complaints

    Complaint rates via the healthcare team web portal

    Time frame: Over a 3 month period

  9. User Satisfaction CHAMP Video

    Feedback from healthcare team will be received via treatment endpoint survey questions. Likert scale questions 1-strongly disagree to 5 strongly agree (Using CHAMP videos for the interstage monitoring of this patient improved clinical decisions for the home monitoring team). Available to put in comments.

    Time frame: through study completion, an average of 9 months

  10. User Satisfaction: Communication

    Feedback from healthcare team will be received via treatment endpoint survey questions Likert scale questions 1-strongly disagree to 5 strongly agree ( Using CHAMP for the interstage monitoring of this patient improved communication with the parents at home.) Available to put in comments.

    Time frame: through study completion, an average of 9 months

  11. User Engagement

    Total number of registered users (Active, treatment endpoint reached) and data totals per parent entered measure. De-identified Demographics and age areas utilization -Utilization across the number of pediatric sites, healthcare teams

    Time frame: Over a 3 month perriod

  12. CHAMP app performance: Downtime

    Product Performance Analytics measured through Any system downtime

    Time frame: Over a 3 month period

  13. CHAMP app performance: Cybersecurity

    Product Performance Analytics measured through Any reported breaches

    Time frame: Over a 3 month period

  14. CHAMP app performance

    Product Performance Analytics measured through --Bug/defect rate or Version failure rates

    Time frame: Quarterly review of CHAMP App Performance will be measure over the preceding 3 months for frequency of changes required

07

Study locations

9 sites
08

References and documents

Publications

  • Shirali G, Erickson L, Apperson J, Goggin K, Williams D, Reid K, Bradley-Ewing A, Tucker D, Bingler M, Spertus J, Rabbitt L, Stroup R. Harnessing Teams and Technology to Improve Outcomes in Infants With Single Ventricle. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):303-11. doi: 10.1161/CIRCOUTCOMES.115.002452. Epub 2016 May 10. PubMed 27166202 ↗
  • Bingler M, Erickson LA, Reid KJ, Lee B, O'Brien J, Apperson J, Goggin K, Shirali G. Interstage Outcomes in Infants With Single Ventricle Heart Disease Comparing Home Monitoring Technology to Three-Ring Binder Documentation: A Randomized Crossover Study. World J Pediatr Congenit Heart Surg. 2018 May;9(3):305-314. doi: 10.1177/2150135118762401. PubMed 29692236 ↗
  • Aly DM, Erickson LA, Hancock H, Apperson JW, Gaddis M, Shirali G, Goudar S. Ability of Video Telemetry to Predict Unplanned Hospital Admissions for Single Ventricle Infants. J Am Heart Assoc. 2021 Aug 17;10(16):e020851. doi: 10.1161/JAHA.121.020851. Epub 2021 Aug 7. PubMed 34365801 ↗
  • Erickson LA, Emerson A, Russell CL. Parental mobile health adherence to symptom home monitoring for infants with congenital heart disease during the single ventricle interstage period: A concept analysis. J Spec Pediatr Nurs. 2020 Oct;25(4):e12303. doi: 10.1111/jspn.12303. Epub 2020 Jul 14. PubMed 32662243 ↗
  • Patel PS, Shah SK, Feldman K, Hancock HS, Moehlmann ML, Ricketts A, Files MD, McFarland C, Erickson L, Romans RA. Associations of Home Monitoring Data to Interventional Catheterization for Infants with Recurrent Coarctation of the Aorta and Hypoplastic Left Heart Syndrome. Pediatr Cardiol. 2023 Oct;44(7):1462-1470. doi: 10.1007/s00246-023-03224-8. Epub 2023 Jul 8. PubMed 37421465 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2027, 52 months after the start.

Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 52 months is above that.

Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Sep 13, 2023
StartActual
Aug 25, 2023
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2027
Nov 18, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Dec 31, 2026→Dec 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06034392
Lead sponsor
Lori Erickson
Responsible party
Lori Erickson (Director, Remote Health Solutions, Children's Mercy Hospital Kansas City) — Sponsor-investigator
First posted
Sep 13, 2023
Start date
Aug 25, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Lori Erickson, PhD
principal investigator · Director, Remote Health Solutions Children's Mercy

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion